Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications
DOI:
https://doi.org/10.31053/1853.0605.v74.n3.15297Keywords:
mitochondrial function, heart failure medication, mitochodrial morphology.Abstract
Background: Mitochondrial activity is essential for cardiac and skeletal muscle. The relationship between mitochondrial dysfunction and different cardiovascular conditions has been well described. Pharmacological treatment for heart failure involves different drugs as: angiotensin-converting enzyme inhibitors, B-adrenergic blockers, digitalis glycosides and diuretics. The clinical benefit from medication is clear, however, the role of this drugs in mitochondrial metabolisms is not well understood. Aim of the study: The objective of our study was to analyze structural and functional characteristics of cardiac and skeletal muscle mitochondria in mice treated with drugs normally used for heart failure and compare it to a control group. Methods: Twenty-five Albino Mice divided in five groups were treated with heart failure medication during 30 days (group I to IV). 30 days after treatment they were sacrificed, heart and skeletal muscle were analyzed and compared with a control group (V). Results: Enzymatic activity was slightly increased in groups treated with heart failure medication compared to control group (p>0.05). Mitochondrial morphology was significantly altered in groups treated compared to control group, in addition, mitochondrial area was significantly increased in the treated groups, in both cardiac and skeletal muscle. Conclusions: We concluded that heart failure medication could produce modifications in mitochondrial function; we believe that mitochondria maintains the enzymatic activity by increasing size and modifying morphology.
Downloads
References
-Organización Mundial de la Salud. Sedentary lifestyle: A Global Public Health Problem. Ginebra: OMS; 2002.
- Francis GS. Pathophysiology of the heart failure clinical syndrome. EL Topol, ed. Textbook ok cardiovascular medicine. Filadelfia, Lippincott-Raven Publishers, 1997.
- Marin-García J. ; Goldenthal MJ. Mitochondria and the heart. Rev Esp Cardiol 2002; 55:1293-1310.
-Marin-Garcia J. Mitochondrial dysfunction in heart failure. J Am Coll Cardiol 2002; 40(12):2174-2181.
-Marin-Garcia J, Goldenthal MJ, Pierpont ME, et al. Impaired mitochondrial function in idiopathic dilated cardiomyopathy: Biochemical and Molecular análisis. J Card Fail 1995;1:285-291.
-Izgi C, Cevik C, Bakal RB, et al. Severe obstructive hypertrophic cardiomyopathy occurring secondary to mitochondrial disease. Turk Kardiyol Dern Ars. 2009 Jul;37(5):332-336.
-Gao L, Laude K, Cai H. Mitochondrial pathophysiology, reactive oxygen species, and cardiovascular diseases. Vet Clin North Am Small Anim Pract 2008; 38(1):137-155.
- Tompkins AJ, Burwell LS, Digerness SB, et al. Mitochondrial dysfunction in cardiac ischemia-reperfusion injury: ROS from complex I, without inhibition. Biochim Biophys Acta 2006;(2):223-231.
- Tsutsi H. Oxidative stress in heart failure : the role of mitochondria. Int. Med 2006; 40, 1177- 1182.
- Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22:6-13.
-Fernando de la Serna. Tratamiento de insuficiencia cardíaca. Actualidad y perspectivas. Rev Fed Arg Cardiol 1999; 28: 217-228.
- Smith TW, Kelly RA, LW Stevenson, et al. The management of heart failure. En: Braunwald E, ed. Heart disease, 5ta ed. Filadelfia, WB Saunders, 1994.
- Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol 1999; 22(6):385-390.
- Oliver H, Lowry Nira J, Rosebrough A, et al. Protein measurement with the folin phenol reagent. J. Biol. Chem 1951;193: 265-275.
- Rickwood, D.; Wilson, M.T.; Darley-Usmar, V.M. En Mitocohondria: A
practical approach (Darley-Usmar, Rickwood, Wilson, eds.) pp 1-16. Oxford, IRL
Press Limited. 1987.
- Trounce IA, Kim YL, Jun AS, et al. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines, Methods Enzymol 1996; 264: 484-509.
- Jarreta D, Orus J, Barrientos A, et al. Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy, Cardivasc. Res 2000; 45: 860-865.
- Seppet E, Gruno M, Peetsalu A, et al. Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci 2009; 19:2252-2303.
-Su B, Wang X, Zheng L, et al. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta 2009;30.
- Nojiri H, Shimizu T, Funakoshi M, et al. Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem. Nov 2006; 3;281(44):3789-3801.
- Marín-García J, Goldenthal MJ. Mitochondrial centrality in heart failure. Heart Fail Rev 2008; 13(2):137-50.
-Guzman Mentesana G, Baez A, Córdoba R, et al. Role of mitochondria and reactive oxygen species in the progression of heart failure. Rev Fac Cien Med Univ Nac Cordoba 2010; 67(4): 150-158.
- Zahorodnyĭ MI, Stechenko LO, Kuftyrieva TP, et al. Influence of lipril on the myocardial ultrastructure in rats with spontaneous hypertension. Lik Sprava. 2008 Jul-Sep;(5-6):82-7.
-de Cavanagh EM, Piotrkowski B, Basso N, et al. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB j 2003; 9:1096-1098.
-de Cavanagh EM, Piotrkowski B, Fraga CG. Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging. Mol Aspects Med 2004; 25(1-2):27-36.
-Tsyganiĭ AA, Medvinskaia NA, Rudenko AF. Effect of digoxin, strophanthin and isolanid on oxygen absorption, oxidative phosphorylation and the amount of cytochromes in the myocardial mitochondria and their ATPase activity. Farmakol Toksikol 1982;45(1):30-32.
-Pereira GC, Silva AM, Diogo CV, et al. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr Pharm Des 2011; 17(20):2113-2129.
-Syed M, Skonberg C, Hansen SH. Mitochondrial toxicity of diclofenac and its metabolites via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria: Possible role in drug induced liver injury (DILI). Toxicol In Vitro 2016; 31:93-102.
-Quinn PJ, Crutcher EC. The action of beta-adrenoceptor antagonists on rat heart mitochondrial function in vitro: a comparison of propranolol, timolol, and atenolol. Cardiovasc Res 1984;18(4):212-219.
-Eknoyan G, Sawa H, Hyde S, et al. Effect of diuretics on oxidative phosphorylation of dog kidney mitochondria. J Pharmacol Exp Ther 1975; 194(3):614-623.
-Ramirez-Ortega M, Zarco G, Maldonado V, et al. Is digitalis compound-induced cardiotoxicity, mediated through guinea-pig cardiomyocytes apoptosis?. Eur J Pharmacol 2007;566(1-3):34-42.
-Gori T, Daiber A, Di Stolfo G, Sicuro S, et al. Nitroglycerine causes mitochondrial reactive oxygen species production: in vitro mechanistic insights. Can J Cardiol 2007; 23(12):990-992.
Downloads
Published
How to Cite
Issue
Section
License
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
